Pancreatic Cancer Research

ResearcherKarolinska University HospitalActive in the last 2 years

Roeland F. de Wilde

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0003-0444-8697; OpenAlex author ID A5001204769, A5003737159. Sources: OpenAlex.

Their work

Papers
43 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
183
Papers, trials and grants by year

2011: 2 papers · 2012: 4 papers · 2013: 1 paper · 2014: none · 2015: 3 papers · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 4 papers · 2024: 8 papers · 2025: 8 papers · 2026: 10 papers

Papers 43

  1. Staging laparoscopy to detect occult metastases in localized pancreatic cancer: global survey among nine international societies. Co-author DOI 10.1016/j.hpb.2025.12.001↗
  2. Response to 'Towards an individualized strategy in perioperative chemotherapy for pancreatic cancer'. Co-author DOI 10.1038/s41416-025-03294-w↗
  3. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  4. Neurogenic diarrhoea after superior mesenteric artery divestment or resection for pancreatic adenocarcinoma following preoperative chemotherapy: international … Co-author DOI 10.1093/bjsopen/zrag057↗
  5. Impact of preoperative radiotherapy on the risk of postpancreatectomy haemorrhage and major morbidity after resection of pancreatic adenocarcinoma including ar… Co-author DOI 10.1093/bjsopen/zrag058↗
  6. Restaging after neoadjuvant FOLFIRINOX for localized pancreatic cancer: a clinical calculator from the Trans-Atlantic Pancreatic Surgery consortium. Co-author DOI 10.1093/jnci/djag024↗
  7. Prediction of resection after preoperative FOLFIRINOX in patients with localized pancreatic adenocarcinoma: a Trans-Atlantic Pancreatic Surgery (TAPS) Consorti… Co-author DOI 10.1093/jnci/djag033↗
  8. Tangential Versus Segmental Portomesenteric Venous Resection During Pancreatoduodenectomy for Pancreatic Cancer: An International Multicenter Cohort Study on S… Co-author DOI 10.1097/sla.0000000000006638↗
  9. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Co-author DOI 10.1200/jco-25-01935↗
  10. The Value of Stereotactic Radiotherapy After FOLFIRINOX in Patients with Pancreatic Cancer with Vascular Contact-A Nationwide, Retrospective Cohort Study. Co-author DOI 10.3390/cancers18040700↗
  11. Adjuvant Chemotherapy After Resection of Localized Pancreatic Adenocarcinoma Following Preoperative FOLFIRINOX. Co-author DOI 10.1001/jamaoncol.2024.5917↗
  12. Minimally Invasive vs Open Left Pancreatectomy for Resectable Pancreatic Cancer: Long-Term Results of the Randomized DIPLOMA Trial. Co-author DOI 10.1001/jamasurg.2025.4054↗
  13. 10-year survival after resection of pancreatic ductal adenocarcinoma with pathological re-examination of a nationwide cohort. Co-author DOI 10.1016/j.ejca.2025.116099↗
  14. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multice… Co-author DOI 10.1016/s1470-2045(25)00363-8↗
  15. Survival after neoadjuvant and induction FOLFIRINOX versus gemcitabine-nab-paclitaxel in patients with resected localised pancreatic adenocarcinoma: an interna… Last author DOI 10.1038/s41416-025-03025-1↗
  16. Carbohydrate antigen 19-9 (CA19-9) response after induction FOLFIRINOX for locally advanced pancreatic cancer identifies patients who may benefit from surgical… Co-author DOI 10.1093/bjs/znaf011↗
  17. Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial. Co-author DOI 10.1097/sla.0000000000006910↗
  18. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  19. Chemotherapy switch for localized pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.1093/bjs/znae244↗
  20. Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study. Co-author DOI 10.1093/jnci/djae070↗
  21. Minimum and Optimal CA19-9 Response After Two Months Induction Chemotherapy in Patients With Locally Advanced Pancreatic Cancer: A Nationwide Multicenter Study. Co-author DOI 10.1097/sla.0000000000006021↗
  22. REDISCOVER International Guidelines on the Perioperative Care of Surgical Patients With Borderline-resectable and Locally Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006248↗
  23. Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy. Co-author DOI 10.1245/s10434-023-14650-6↗
  24. ASO Author Reflections: Nationwide Experience on Locally Advanced Pancreatic Cancer Surgery After Induction Chemotherapy in the Netherlands: A Stepping Stone f… Co-author DOI 10.1245/s10434-023-14704-9↗
  25. Surgical Outcome After Distal Pancreatectomy With and Without Portomesenteric Venous Resection in Patients with Pancreatic Adenocarcinoma: A Transatlantic Eval… Co-author DOI 10.1245/s10434-024-15932-3↗
  26. ASO Author Reflections: Distal Pancreatectomy With and Without Portomesenteric Venous Resection for Pancreatic Adenocarcinoma: A Transatlantic Evaluation of Pa… Co-author DOI 10.1245/s10434-024-16021-1↗
  27. Nationwide evaluation of pancreatic cancer networks ten years after the centralization of pancreatic surgery. Co-author DOI 10.1016/j.hpb.2023.07.904↗
  28. Minimally invasive versus open distal pancreatectomy for resectable pancreatic cancer (DIPLOMA): an international randomised non-inferiority trial. Co-author DOI 10.1016/j.lanepe.2023.100673↗
  29. B cell immune profiles in dysbiotic vermiform appendixes of pancreatic cancer patients. Co-author DOI 10.3389/fimmu.2023.1230306↗
  30. [Resection of locally advanced pancreatic cancer: careful selection and shared decision making]. Co-author PMID 37994726↗
  31. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomised controlled trials. Co-author DOI 10.1016/j.ejca.2021.10.023↗
  32. Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.1245/s10434-021-10276-8↗
  33. Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma. Co-author DOI 10.1038/s41416-019-0683-3↗
  34. Proteins associated with pancreatic cancer survival in patients with resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/labinvest.2014.128↗
  35. Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function. Co-author DOI 10.1158/0008-5472.can-15-0108↗
  36. Very Long-term Survival Following Resection for Pancreatic Cancer Is Not Explained by Commonly Mutated Genes: Results of Whole-Exome Sequencing Analysis. Co-author DOI 10.1158/1078-0432.ccr-14-2600↗
  37. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2013.01.054↗
  38. Pancreatic ductal adenocarcinoma in hereditary diffuse gastric cancer. A case report. First author DOI 10.1016/j.humpath.2011.06.008↗
  39. Molecular determinants of retinoic acid sensitivity in pancreatic cancer. Co-author DOI 10.1158/1078-0432.ccr-11-2165↗
  40. The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models. Co-author DOI 10.1158/1535-7163.mct-12-0017↗
  41. Stromal galectin-1 expression is associated with long-term survival in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.4161/cbt.20842↗
  42. mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome. Co-author DOI 10.1200/jco.2010.32.7825↗
  43. Molecular characteristics of pancreatic ductal adenocarcinoma. First author DOI 10.4061/2011/620601↗

Closest collaborators

The 25 strongest of 183 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 18 shared papers, 2021–2026 · strength 3.27
  2. Bas Groot Koerkamp · 16 shared papers, 2021–2026 · strength 2.95
  3. Casper H.J. van Eijck · 10 shared papers, 2021–2026 · strength 1.66
  4. Thomas F. Stoop · 9 shared papers, 2024–2026 · strength 1.60
  5. Hjalmar C. van Santvoort · 9 shared papers, 2021–2026 · strength 1.55
  6. Johanna W. Wilmink · 9 shared papers, 2021–2026 · strength 1.53
  7. Esther N. Dekker · 7 shared papers, 2024–2026 · strength 1.42
  8. Izaak Quintus Molenaar · 7 shared papers, 2023–2026 · strength 1.27
  9. Eva M M Verkolf · 6 shared papers, 2024–2026 · strength 1.25
  10. Matthew H. G. Katz · 6 shared papers, 2024–2026 · strength 1.22
  11. Marjolein Y.V. Homs · 7 shared papers, 2021–2026 · strength 1.19
  12. Christopher Lee Wolfgang · 8 shared papers, 2015–2026 · strength 1.15
  13. Poya Ghorbani · 6 shared papers, 2024–2026 · strength 1.07
  14. Marco Del Chiaro · 6 shared papers, 2024–2026 · strength 1.07
  15. Ignace H. J. T. de Hingh · 6 shared papers, 2023–2026 · strength 1.05
  16. Quisette P. Janssen · 6 shared papers, 2021–2026 · strength 1.05
  17. Martijn W.J. Stommel · 6 shared papers, 2023–2026 · strength 0.98
  18. Leonard W. F. Seelen · 5 shared papers, 2023–2026 · strength 0.96
  19. Geert Kazemier M · 5 shared papers, 2025–2026 · strength 0.88
  20. Jacob L. van Dam · 5 shared papers, 2021–2026 · strength 0.85
  21. J. Sven D. Mieog · 5 shared papers, 2024–2026 · strength 0.83
  22. Alice Chia-Chi Wei · 4 shared papers, 2021–2026 · strength 0.83
  23. Ingmar Florin Rompen · 4 shared papers, 2026 · strength 0.76
  24. Richard David Schulick · 4 shared papers, 2026 · strength 0.76
  25. Rutger T. Theijse · 4 shared papers, 2025–2026 · strength 0.75

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.